X

News

September 2013: VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

A preclinical study led by researchers at Children’s National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug,

More >

August 2011: ReveraGen BioPharma Selected as Awardee for Inaugural National Institutes of Health’s Therapeutics for Rare and Neglected Diseases Program for its Novel Dissociative Glucocorticoid Analogue

Rockville, MD – ReveraGen BioPharma, Inc., a biopharmaceutical company developing alternatives to traditional steroid compounds, including dissociative glucocorticoid analogues for use in muscular dystrophy, has been selected by the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases

More >

August 2011: Former MedImmune exec becomes CEO of startup

Under-the-radar ReveraGen BioPharma Inc., a Rockville-based biotech, has recruited former MedImmune executive Edward Connor to helm the small operation, which hopes to bring a better treatment for Duchenne muscular dystrophy to market.
More >